Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 21, 2022; 28(23): 2582-2596
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2582
Published online Jun 21, 2022. doi: 10.3748/wjg.v28.i23.2582
Variable | Week 14 (after initial IFX therapy), n = 93 | Week 14 (after initial IFX therapy), n = 54 | ||||||
Predict endoscopic relapse at week 54 | Predict endoscopic relapse at week 108 | |||||||
Univariate analysis | Multivariable analysis | Univariate analysis | Multivariable analysis | |||||
OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | |
Median age in year, median (IQR) | 0.997 (0.950-1.047) | 0.904 | — | — | 1.028 (0.967-1.093) | 0.381 | — | — |
Course in year, median (IQR) | 1.054 (0.945-1.176) | 0.346 | — | — | 1.065 (0.906-1.253) | 0.444 | — | — |
Male sex, n (%) | 0.478 (0.191-1.199) | 0.116 | — | — | 0.700 (0.188-2.607) | 0.595 | — | — |
Disease location, n (%) | ||||||||
L1 (terminal ileum) | 0.413 (0.114-1.495) | 0.178 | — | — | 1.158 0.117-11.454) | 0.900 | — | — |
L2 (colon) | 1.453 (0.430-4.908) | 0.548 | — | — | 3.000 (0.341-26.427) | 0.322 | — | — |
L3 (ileocolon) | — | — | — | — | — | — | — | — |
L4 (upper digestive tract) | 1.277 (0.452-3.612) | 0.645 | — | — | 0.939 (0.215-4.113) | 0.934 | — | — |
Disease behavior, n (%) | ||||||||
B1 (no) | — | — | — | — | — | — | — | — |
B2 (stenosis) | 0.889 (0.345-2.294) | 0.808 | — | — | 0.600 (0.141-2.561) | 0.490 | — | — |
B3 (penetration) | 1.860 (0.658-5.264) | 0.242 | — | — | 0.700 (0.188-2.607) | 0.595 | — | — |
B2 (stenosis) + B3 (penetration) | — | — | — | — | — | — | — | — |
Perianal diseases, n (%) | 1.442 (0.562-3.696) | 0.446 | — | — | 0.952 (0.259-3.502) | 0.941 | — | — |
Previous medical therapy, n (%) | 1.027 (0.386-2.736) | 0.957 | 2.040 (0.481-8.650) | 0.333 | ||||
Previous surgical therapy, n (%) | 0.926 (0.266-3.218) | 0.903 | — | — | — | — | — | — |
Laboratory indicators, median (IQR) | ||||||||
Fecal calprotectin, μg/g | 1.003 (1.002-1.005) | 0.000 | 1.002 (1.001-1.004) | 0.002 | 1.002 (1.001-1.004) | 0.001 | NS | NS |
IFX trough level, μg/mL | 0.650 (0.532-0.796) | 0.000 | 0.666 (0.514-0.862) | 0.002 | 0.470 (0.289-0.766) | 0.002 | 0.466 (0.247-0.877) | 0.018 |
White blood count, x 109/L | 1.167 (0.921-1.478) | 0.201 | — | — | 1.004 (0.636-1.586) | 0.986 | — | — |
Hematoglobin, g/L | 0.977 (0.954-1.000) | 0.053 | — | — | 0.997 (0.957-1.038) | 0.867 | — | — |
Platelet, x 109/L | 1.006 (0.999-1.013) | 0.081 | — | — | 1.001 (0.987-1.015) | 0.904 | — | — |
Erythrocyte sedimentation rate, mm/h | 1.073 (1.028-1.120) | 0.001 | NS | NS | 1.035 (0.978-1.096) | 0.239 | — | — |
Albumin, g/L | 0.895 (0.800-1.002) | 0.054 | — | — | 0.821 (0.667-1.010) | 0.062 | — | — |
C-reactive protein, mg/dL | 1.245 (1.080-1.435) | 0.003 | NS | NS | 1.389 (1.070-1.804) | 0.014 | 1.590 (1.007-2.510) | 0.047 |
- Citation: Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596
- URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i23.2582